Invivyd, Inc.
No SEC Form 4 filings for $IVVD in the last 30 days.
See all $IVVD insider activity →Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.
Invivyd, Inc. (Nasdaq: IVVD) granted options to 6 new employees to buy 157,500 shares at $0.8165 each. The options vest over 4 years and have a 10-year term. Invivyd is a biopharmaceutical company focused on viral infectious diseases, with an FDA EUA for a monoclonal antibody.
Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning IVVD (Invivyd, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent IVVD coverage spans financial news, corporate actions and technology.
The trial start adds a positive catalyst for Invivyd, potentially lifting the stock as investors price in future efficacy data.
The option grant modestly dilutes existing shareholders and may slightly pressure the stock.
Positive trial data and regulatory filing plans are likely to boost investor confidence.
Positive safety data may boost investor confidence and support a higher valuation ahead of the BLA filing.
Leadership change may influence strategic direction and investor sentiment; trial updates could affect near‑term valuation.
AlphAI scores every news story that mentions IVVD with an AI model for sentiment and relevance, and aggregates insider trades from Invivyd, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.
2 min readInvivyd, Inc. (Nasdaq: IVVD) granted options to 6 new employees to buy 157,500 shares at $0.8165 each. The options vest over 4 years and have a 10-year term. Invivyd is a biopharmaceutical company focused on viral infectious diseases, with an FDA EUA for a monoclonal antibody.
1 min readInvivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing
2 min readInvivyd (IVVD) reported that its COVID-19 monoclonal antibody VYD2311 met primary safety endpoints in the Phase 3 LIBERTY study, showing favorable safety and tolerability compared to an mRNA vaccine. The study enrolled 210 healthy adults, with 56.5% of VYD2311 recipients experiencing adverse events versus 91.4% for the vaccine. The company plans to use the data to support a BLA submission to the FDA. IVVD stock closed at $0.95, up 1.69%, and is trading at $0.99 in pre-market.
2 min readInvivyd, Inc. (IVVD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY • Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate s
2 min readInvivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollme
6 min readInstitutional investors in Invivyd, Inc. (NASDAQ:IVVD) experienced a US$113 million decrease in market cap last week due to a 16% drop in holdings value. Despite this, they have benefited from a 397% one-year return. Institutions collectively hold 39% of the company's shares, with hedge funds owning an additional 20%, indicating significant influence over Invivyd's share price.
4 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. D. Boral Capital analyst Jason Kolbert downgraded the rating for Invivyd Inc ( NASDAQ:IVVD ) ...
3 min readNEW HAVEN, Conn., Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. ( Nasdaq: IVVD ) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL.
3 min readAntiviral potency 1.5-fold greater on average than nirsevimab and 1.2-fold greater on average than clesrovimab against established authentic RSV strains representing circulating variants
2 min read